Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Partial alignment only for some composition/mechanism and certain safety statements; multiple claims are unsupported or not directly reflected in the provided label excerpts (e.g., exacerbation reduction, “bronchospasm” phrasing in indication, “common” adverse-effect framing, “makes it easier to breathe,” and manufacturer attribution).
Category Scores
Accurate Statements
Anoro Ellipta contains umeclidinium.
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action.
Umeclidinium is a long-acting muscarinic antagonist (LAMA).
Supported by 12.1 Mechanism of Action.
Anoro Ellipta contains vilanterol.
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action.
Vilanterol is a long-acting beta2-adrenergic agonist (LABA).
Supported by 12.1 Mechanism of Action.
More serious, but less common, side effects can include paradoxical bronchospasm.
Supported by 5.5 Paradoxical Bronchospasm.
More serious, but less common, side effects can include cardiovascular effects.
Supported by 5.7 Cardiovascular Effects.
More serious, but less common, side effects can include hypersensitivity reactions.
Supported by 5.6 Hypersensitivity Reactions, including Anaphylaxis.
Diarrhea is an adverse reaction of Anoro Ellipta.
Supported by 6.1 Clinical Trials Experience (Table 1 includes Diarrhea).
Chest pain is an adverse reaction of Anoro Ellipta.
Supported by 6.1 Clinical Trials Experience (Table 1 includes Chest pain).
Unsupported Statements
Anoro is manufactured by GlaxoSmithKline (GSK) and Pfizer.
No manufacturer information is present in the provided label excerpts.
Anoro Ellipta is used to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The provided indication/usage text states maintenance treatment only; no exacerbation-reduction claim is present in the supplied excerpts.
Umeclidinium makes it easier to breathe.
Provided label excerpts describe bronchodilation mechanistically but do not state this patient-facing claim.
Common side effects of Anoro Ellipta include nasopharyngitis.
Nasopharyngitis is not listed in the supplied adverse-reaction excerpts (pharyngitis appears instead).
Contradictions
Important Omissions
Contraindications, boxed warnings, and dosing/administration safety details (e.g., sections 2/4/boxed warning content) were not provided; therefore compliance for these label-critical safety areas cannot be evaluated.
Importance:
High
The AI claims include multiple safety framing elements (e.g., “common,” “more serious, but less common”) without corresponding provided-label frequency/wording for those specific terms across all listed adverse reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety statements align with provided label sections (paradoxical bronchospasm, cardiovascular effects, hypersensitivity). However, multiple claims are unsupported or not anchored to the provided label wording, and key safety-domain sections (contraindications/boxed warnings/dosing) were not included, limiting verification of critical risk information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several substantive claims are unsupported by the provided label excerpts (exacerbation reduction; nasopharyngitis as common; patient-facing “easier to breathe”; manufacturer attribution; exact indication phrasing).
Suggested Improvement
Limit claims to elements explicitly present in the provided label text (e.g., maintenance treatment for COPD; components and mechanisms; safety warnings described in 5.5/5.6/5.7; adverse reactions listed in the provided 6.1 excerpts) and avoid unsourced frequency or patient-facing efficacy phrasing not directly reflected in the excerpts.